This document provides financial and stock performance data for Celltrion Pharm over several periods from 2016-2019. It includes key metrics like sales, operating profit, net income, debt ratio, and stock price. It also provides the company's stock indication price range, the current stock price, and evaluation of the stock's probability to rise based on an analysis algorithm. Purchase amounts are suggested based on the stock's position within its indication price range.
1. Performance Analysis of Algorithm (consolidated) 068760 Date
Period 3 months 100-m won
2016.12 2017.12 2018.12 Average 2018.09 2018.12 2019.03 2019.06 2019.09 2019.12
IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con) IFRS(Con)
Sales 1,048 1,359 1,469 1,292 347 505 386 426 468 513 416
O-profit 73 87 36 65 -22 46 18 36 77 167 20
N-income 29 27 -94 -13 -38 -35 3 20 65 213 -13
O-rate 7.0 6.4 2.5 5.3 -6.3 9.1 4.7 8.5 16.6 32.4 4.0
N-rate 2.8 2.0 -6.4 -0.5 -11.0 -6.9 0.8 4.7 14.0 41.6 -3.1
ROE 0.8 0.9 -3.5 -0.6 -5.7 -5.4 -3.5 -2.9 -1.6 2.1 -4.4
Debt-ratio 48.0 60.1 67.6 58.6 67.7 67.6 64.9 68.9 70.7 72.6 67.3
Quick-ratio 146.3 117.3 108.9 124.2 93.4 108.9 106.6 103.6 111.6 128.0 103.1
reserve-ratio 2,072.8 1,653.3 1,486.5 1,737.5 1,481.8 1,486.5 1,465.3 1,500.6 1,439.8 1,392.6 1,483.5
EPS 85 79 -276 -37 -111 -103 9 59 192 626 -37
BPS 10,109 8,613 7,920 8,881 7,891 7,920 7,935 8,003 7,960 7,918 7,937
Dividends 0 0 0 0
Major
Financial
Information
Recent Annual Performance Recent quarterly performance Estimate
Average
2019-09-30
Gap
(Indication /
stock)
Color
High price ~ 37 %
High mid ~ 18 %
Mid ~ -1 %
Low mid ~ -20 %
Low price ~ -39 %
Normal
21,260 W 21,260 W 0 W
Industrial name of the company
The number of
All industries
Algorithm
Industry ranking
Total number of
listed companies
Algorithm
company ranking
Investment
opinion
Pharmaceutical 81 40 3,009 1,911
41,043 W 41,043 W 34,449 W
34,449 W 34,449 W 27,854 W Evaluation
47,638 W 47,638 W~ 41,043 W
34,850 W
42.527,854 W 27,854 W 21,260 W
High mid
Indication price Range Current stock price Company score
21,260원
27,854원
34,449원
41,043원
47,638원
High mid 34,850원
-39%
-20%
-1%
17.8%
36.7%
-50%
-40%
-30%
-20%
-10%
0.%
10.%
20.%
30.%
40.%
50.%
0W
10,000W
20,000W
30,000W
40,000W
50,000W
60,000W
Low price Low mid Mid High mid High price
Indication price chart (Consolidated)
Indication price
Celltrion Pharm
Gap
Celltrion Pharm
2. [Price for scheduled purchasing]
Arbitrarily made
Algorithm stocks Trading Strategies (consolidated) 068760 Date
Period
Gap
(Indication /
stock)
Color
low price 21,260 W 21,260 W ~ 0 W -39 % 145,647 W 7
Low mid 27,854 W 27,854 W ~ 21,260 W -20 % 74,973 W 3
Mid 34,449 W 34,449 W ~ 27,854 W -1 % 4,299 W 0
High mid 41,043 W 41,043 W ~ 34,449 W 18 % -66,375 W -2
Suggested Purchase
Amount 373,492 W
Number of stocks
purchased 11
Indication price Range Buying / Selling Buying / Selling [Stocks]
High price 47,638 W 47,638 W~ ~ 41,043 W 37 % -137,049 W -3
2019-09-30
3 months
Current stock price Evaluation
Stock price rise
probability score
Investment opinion Prospective purchase amount
34,850 W High mid 39.2 Normal 1,500,000 W
40.1 46.2 36.9 12.5 37.9 49.4
2019.05.03 2019.06.03 2019.07.02 2019.07.30 2019.08.28 2019.09.27
Stock price rise
probability score
A Sector 46.8 43.6 46.7 43.8 47.5 50.4
39.2B Sector 33.3 48.8 27.1 43.8 28.3 48.3
Total average
2019.07.02 2019.07.30 2019.08.28 2019.09.27
Total of
increase rate
Total score
A Sector -7 % 7 % -7 % 8 % 6 %
-23 % 49.3B Sector 32 % -80 % 38 % -54 % 41 %
Total average 13 % -25 % -195 % 67 % 23 %
2019.06.03
47
44
47
44
48
50
33
49
27
44
28
48
40
46
37
13
38
49
0
10
20
30
40
50
60
2019.05.03 2019.06.03 2019.07.02 2019.07.30 2019.08.28 2019.09.27
Stock price rise probability score
A sector
B sector
Total average
-7%
7% -7%
8% 6%
32%
-80%
38%
-54%
41%
13%
-25%
-195%
67%
23%
-250%
-200%
-150%
-100%
-50%
0%
50%
100%
2019.06.03 2019.07.02 2019.07.30 2019.08.28 2019.09.27
Increase rate of stock price rise
A sector
B sector
Total average
Celltrion Pharm
3. 정보와
완전
정보
결
투자판단
있습니
위배
무단으
숙지하
Compliance notice
① The information provided by The Algorithm Company Analysis
Consulting is obtained through reliable data and information and
The Algorithm Company Analysis Program (TACAP), but its
accuracy or completeness are not guaranteed. Furthermore, it may
change over time.Therefore, we are not legally responsible for the
results of the data provided by The Algorithm Company Analysis
Consulting because of information errors or omissions.
② The Algorithm Company Analysis Consulting and all the
information provided on it site are reference materials for
investment decisions and the final responsibility of investment is
up to users utilizing this information.
③ The Algorithm Company Analysis Consulting and its site do not
do anything that violates the related laws such as discretionary
transaction.
④ Users can not reallocate and recycle the information provided by
The Algorithm Company Analysis Consulting firm let alone the
information provided by its Site.
⑤ Be sure to know about application period of this algorithm
analysis report in order to improve its accuracy.
Tel : 070 - 4667 - 5009 Email : tacac@tacac.co.kr
Homepage : tacac.co.kr Blog : tacac.blog.me
SERVICES
M&A, IPO, RECOVER, CORPORATE RESTRUCTURING, MANAGEMENT OF
TECHNOLOGY, BUSINESS STRATEGY, FAMILY BUSINESS
Request : http://tacac.co.kr/?page_id=1374
①
Consulting
The Algori
accuracy o
change ove
results of
Consulting
②
informatio
investmen
up
③
do anythin
transaction
④
The Algori
informatio
⑤
analysis re